• Explore /
  • Poster
  • / Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: A multicenter, open-label, single-arm phase 2 study.

Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: A multicenter, open-label, single-arm phase 2 study.

Abstract Poster

Authors

null

Lili Mao

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China

Lili Mao , Meiyu Fang , Yu Chen , Xue Bai , Jun Cao , Jing Lin , Peng Zhang , Ling Chen , Jiahui Xu , Jun Guo , Lu Si

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04091217

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9525)

DOI

10.1200/JCO.2022.40.16_suppl.9525

Abstract #

9525

Poster Bd #

118

Abstract Disclosures

Similar Posters

First Author: Kazuomi Ueshima

First Author: Kanwal Pratap Singh Raghav

First Author: Aiwu Ruth He

First Author: Daneng Li